Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
175.62B
Market cap175.62B
Price-Earnings ratio
25.21
Price-Earnings ratio25.21
Dividend yield
2.92%
Dividend yield2.92%
Average volume
2.07M
Average volume2.07M
High today
$332.08
High today$332.08
Low today
$323.89
Low today$323.89
Open price
$328.82
Open price$328.82
Volume
2.12M
Volume2.12M
52 Week high
$346.38
52 Week high$346.38
52 Week low
$260.55
52 Week low$260.55

Stock Snapshot

With a market cap of 175.62B, Amgen(AMGN) trades at $326.09. The stock has a price-to-earnings ratio of 25.21 and currently yields dividends of 2.9%.

On 2026-01-12, Amgen(AMGN) stock moved within a range of $323.89 to $332.08. With shares now at $326.09, the stock is trading +0.7% above its intraday low and -1.8% below the session's peak.

Trading activity shows a volume of 2.12M, compared to an average daily volume of 2.07M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $346.38 and a low of $260.55.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $346.38 and a low of $260.55.

AMGN News

Simply Wall St 1d
How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen Investors

Earlier this month, DISCO Pharmaceuticals announced an exclusive license agreement granting Amgen global rights to develop and commercialize cancer therapies fr...

How Amgen’s DISCO Oncology Licensing Deal Will Impact Amgen Investors
Simply Wall St 3d
Amgen Valuation Check After DISCO Oncology Deal And Fresh Analyst Optimism

Amgen (AMGN) has just entered an exclusive license agreement with DISCO Pharmaceuticals, giving it global rights to develop cancer therapies based on DISCO's ce...

Amgen Valuation Check After DISCO Oncology Deal And Fresh Analyst Optimism
TipRanks 4d
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

Analyst ratings

48%

of 33 ratings
Buy
48.5%
Hold
42.4%
Sell
9.1%

More AMGN News

Nasdaq 4d
Can These Dividend Stocks Beat the Market Again in 2026?

Key Points Building on a strong 2025, CVS Health's outlook for 2026 and beyond looks promising. Amgen is developing newer drug products that will address a re...

Can These Dividend Stocks Beat the Market Again in 2026?
Nasdaq 4d
Amgen Reaches Analyst Target Price

In recent trading, shares of Amgen Inc (Symbol: AMGN) have crossed above the average analyst 12-month target price of $242.67, changing hands for $243.12/share....

Amgen Reaches Analyst Target Price
Benzinga 5d
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

On Tuesday, Amgen Inc. (NASDAQ:AMGN) acquired Dark Blue Therapeutics, a discovery and development biotech company focused on precision oncology medicines. The...

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
TipRanks 5d
Amgen Advances Early-Stage Obesity Candidate With New Injection Trial

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

Nasdaq 5d
Dow Movers: JPM, AMGN

In early trading on Wednesday, shares of Amgen topped the list of the day's best performing Dow Jones Industrial Average components, trading up 2.6%. Year to da...

Dow Movers: JPM, AMGN
Nasdaq 5d
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline

Amgen AMGN announced that it has acquired U.K.-based private biotech company, Dark Blue Therapeutics, for approximately $840 million. The acquisition will stre...

Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline
Simply Wall St 5d
Amgen Is Increasing Its Dividend To $2.52

Amgen Inc. ( ) will increase its dividend from last year's comparable payment on the 6th of March to $2.52. The payment will take the dividend yield to 3.1%, wh...

Amgen Is Increasing Its Dividend To $2.52

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.